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Abstract
Background: Innovative approaches are needed to complement existing tools for malaria elimination. Ivermectin is a broad
spectrum antiparasitic endectocide clinically used for onchocerciasis and lymphatic filariasis control at single doses of 150 to
200 mcg/kg. It also shortens the lifespan of mosquitoes that feed on individuals recently treated with ivermectin. However, the
effect after a 150 to 200 mcg/kg oral dose is short-lived (6 to 11 days). Modeling suggests higher doses, which prolong the
mosquitocidal effects, are needed to make a significant contribution to malaria elimination. Ivermectin has a wide therapeutic
index and previous studies have shown doses up to 2000 mcg/kg (ie, 10 times the US Food and Drug Administration approved
dose) are well tolerated and safe; the highest dose used for onchocerciasis is a single dose of 800 mcg/kg.
Objective: The aim of this study is to determine the safety, tolerability, and efficacy of ivermectin doses of 0, 300, and 600
mcg/kg/day for 3 days, when provided with a standard 3-day course of the antimalarial dihydroartemisinin-piperaquine (DP), on
mosquito survival.
Methods: This is a double-blind, randomized, placebo-controlled, parallel-group, 3-arm, dose-finding trial in adults with
uncomplicated malaria. Monte Carlo simulations based on pharmacokinetic modeling were performed to determine the optimum
dosing regimens to be tested. Modeling showed that a 3-day regimen of 600 mcg/kg/day achieved similar median (5 to 95
percentiles) maximum drug concentrations (Cmax) of ivermectin to a single of dose of 800 mcg/kg, while increasing the median
time above the lethal concentration 50% (LC50, 16 ng/mL) from 1.9 days (1.0 to 5.7) to 6.8 (3.8 to 13.4) days. The 300 mcg/kg/day
dose was chosen at 50% of the higher dose to allow evaluation of the dose response. Mosquito survival will be assessed daily up
to 28 days in laboratory-reared Anopheles gambiae s.s. populations fed on patients’ blood taken at days 0, 2 (Cmax), 7 (primary
outcome), 10, 14, 21, and 28 after the start of treatment. Safety outcomes include QT-prolongation and mydriasis. The trial will
be conducted in 6 health facilities in western Kenya and requires a sample size of 141 participants (47 per arm). Sub-studies
include (1) rich pharmacokinetics and (2) direct skin versus membrane feeding assays.
Results: Recruitment started July 20, 2015. Data collection was completed July 2, 2016. Unblinding and analysis will commence
once the database has been completed, cleaned, and locked.
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Conclusions: High-dose ivermectin, if found to be safe and well tolerated, might offer a promising new tool for malaria
elimination.
(JMIR Res Protoc 2016;5(4):e213)   doi:10.2196/resprot.6617
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Introduction
Ivermectin is a potential new tool that is being considered in
malaria transmission reduction strategies [1]. Ivermectin is a
broad spectrum antiparasitic endectocide active against a wide
range of internal and external parasites. It was originally
introduced as a veterinary drug, predominantly for use in
domestic livestock, but since 1987 has been widely used in
human medicine [2]. Ivermectin at a dose of 150 or 200 mcg/kg
is the first-line treatment for Onchocerca volvulus (the cause of
river blindness) [3], Wuchereria bancrofti (the cause of
lymphatic filariasis) [4], and Strongyloides stercoralis
(roundworm, an intestinal helminth) [5]. To date more than 2.7
billion treatments have been distributed as part of mass drug
administration (MDA) [6].
Ivermectin has secondary effects on ectoparasites, such as head
lice, mites, bedbugs, and scabies, that feed on recently treated
individuals [2,7], and it is also active against Anopheles spp. at
concentrations present in human blood after standard doses. It
reduces the re-blood feeding capacity, female fecundity, hatch
rate of their eggs, the survival of progeny larvae, and
importantly, it reduces the vector’s lifespan [1,8-11]. It may
also inhibit parasite sporogony [12]. Ivermectin has a different
mode of action from other insecticides, and therefore may be
effective against mosquito populations that are resistant to
insecticides used on long-lasting insecticidal nets (LLINs) or
indoor residual spraying (IRS). Furthermore, it is able to kill
exophagic and exophillic vectors that can escape the indoor
killing effects of LLINs and IRS [8].
However, several studies have shown that the effects after the
standard 150 to 200 mcg/kg doses of ivermectin are generally
short-lived. Three in vivo studies assessed the long-term effect
of ivermectin on mosquito survival by conducting feedings at
least 7 days after administration of ivermectin [10,13,14]. A
single low dose of 200 mcg/kg showed a 1.33 fold increase in
mosquito mortality when fed on blood taken from humans who
had received ivermectin 1 day earlier, but there was no longer
an effect when mosquitoes were fed on blood taken on day 14
post-treatment [10], while a repeated dose of 200 mcg/kg given
on days 0 and 2 showed a modest effect on reduced survival 7
days post-treatment [14], and a dose of 250 mcg/kg in a single
human volunteer showed a potent effect for at least 2 weeks
post-treatment [13]. Population-based studies of the effect of
MDA with ivermectin on malaria transmission or mosquito
survival showed that MDA with a single dose of 150 mcg/kg
for the control of onchocerciasis in Senegal affected survivorship
of An. gambiae s.s. for up to 6 days, resulting in an estimated
reduction of malaria transmission for at least 11 days as a result
of a change in the age-structure of An. gambiae s.s. [15-17].
Similarly, in 3 different West African transmission settings, this
same dose reduced An. gambiae survivorship by 33.9% for 1
week, their parity rates for more than two weeks, and sporozoite
rates by more than 77% for 2 weeks [18].
Modeling has also shown that adding 3 days of ivermectin (150
mcg/kg/day) to MDA with dihydroartemisinin-piperaquine (DP)
would potentially provide an important boost to the effect of
MDAs with artemisinin-based combination therapy (ACT) by
allowing transmission to be interrupted faster and in areas with
a higher malaria prevalence than MDA with ACTs alone [19].
However, the effects are modest, and higher doses, providing
a longer effect are required for ivermectin to boost malaria
transmission reduction activities [19].
Ivermectin 400 mcg/kg has been suggested as an improved
treatment for head lice [20], and has been found to be safe and
well tolerated [21]. No studies in humans have compared the
effect of ivermectin doses above 400 mcg/kg on the ability of
anopheline vectors to transmit malaria (henceforth referred to
as infectivity), or evaluated the effect of any dose of ivermectin
higher than 400 mcg/kg on mosquito survivorship.
Ivermectin has an excellent safety profile [1], and experience
with higher doses show that it is remarkably well tolerated in
humans [22-27], even at doses up to 2000 mcg/kg, 10 times the
200 mcg/kg dose currently approved by the US Food and Drug
Administration [24] (Table 1). In invertebrates, ivermectin
causes the opening of glutamate-gated chloride channels
resulting in flaccid paralysis and death [28]. Glutamate-gated
chloride channels do not exist in humans. Other weakly sensitive
channels are found in the human central nervous system, but
the blood-brain barrier limits drug access to these channels [29].
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Table 1. Studies of safety and tolerability of ivermectin incorporating dosages greater than or equal to 800 mcg/kg.
Adverse events: increased vs
control
Single doses in mcg/kg
(n)
Total study population, nParticipants with
single dose ≥800
mcg/kg, n
Highest single doseReference
No150 (15), 400a (25), 600a
(24), 800a (24), 800b (12)
100 adult males with on-
chocerciasis in Ghana
36800 mcg/kgAwadzi 1995,
1999 [22,23]
No0 (17), 500c (15), 1000c
(12), 1500 (12), 2000
(12)
68 healthy adults, non-preg-
nant, in the United States
362000 mcg/kgGuzzo 2002
[24]
Transitory mild visual side
effects, without structural ab-
normalities upon ophthalmo-
logical exam
150d (327), 800d,e (330)657 adult males with on-
chocerciasis in Cameroon
330800 mcg/kgKamgno 2004
[25-27]
aPreceded 3 days earlier by 150 mcg/kg or placebo.
bPreceded 13 days earlier by 800 mcg/kg.
cRepeated 3 times a week (days 1, 4, and 7).
dRepeated 3 times monthly or once yearly.
ePreceded 3 or 12 months earlier by 400 mcg/kg.
The only known severe adverse events have been in individuals
with Loa loa, possibly due to rapid lysis of parasite biomass
[30]. Assessment of Loa loa is recommended before ivermectin
administration in areas endemic for Loa loa filariasis [31].
DP and ivermectin have, to the best of our knowledge, never
been studied under simultaneous administration. Piperaquine,
the long-acting component of DP, is metabolized by, and is an
inhibitor of, cytochrome-P450 3A4 (CYP3A4) [32]. There is a
potential for an increase of piperaquine plasma concentrations
when it is co-administered with other CYP3A4 substrates (due
to competition) or CYP3A4 inhibitors [32]. Dihydroartemisinin
(DHA), the short-acting component of DP, is not metabolized
by cytochrome-P450, but is deactivated via glucuronidation
catalyzed by UDP-glucuronosyltransferases, in particular
UGT1A9 and UGT2B7 [33]. DHA has been shown to induce
CYP3A activity and also up-regulate CYP2C19 and CYP2B6
[33]. DHA is a known inhibitor of CYP1A2 [32].
Ivermectin is primarily metabolized by CYP3A4 [34]. In vitro
studies using human liver microsomes suggest that ivermectin
does not significantly inhibit the metabolizing activities of
CYP3A4, CYP2D6, CYP2C9, CYP1A2, and CYP2E1 [34].
When DP and ivermectin are administered together, however,
there may be some competition for CYP3A4. The
CYP3A4-inhibitory properties of piperaquine may lead to an
increased availability of ivermectin. As ivermectin is not a
CYP3A4-inhibitor, the potential increase in the availability of
piperaquine due to competition is expected to be low.
We will conduct a placebo-controlled dose-finding study to
determine the safety, tolerability, and mosquitocidal effect of
3-day courses of ivermectin when given in combination with a
standard 3-day course of DP to identify safe and practical
regimens to boost the arsenal of available tools to reduce or
interrupt malaria transmission. Pharmacokinetic data will be
collected to facilitate the construction of a
pharmacokinetic/pharmacodynamic (PK/PD) model to guide
future study design.
Methods
Design Overview
This is a double-blind, randomized, placebo-controlled,
parallel-group, 3-arm, superiority trial to determine the safety,
tolerability, and mosquitocidal effect of different doses of
ivermectin (ClinicalTrials.gov: NCT02511353). The primary
endpoint will be mosquito survival 14 days after a blood feed
from a patient who started ivermectin 7 days earlier; 5 days after
the last dose of ivermectin with a 3-day regimen administering
ivermectin at 0, 24, and 48 hours (days 0, 1 and 2). Because
mosquito feeding involves approximately 100 mosquitoes per
feed, the study will use a clustered design with the patient as
the unit of randomization and the mosquito as the unit of
analysis. The study will have a nested rich pharmacokinetic
component in the first 36 patients that give additional consent
for rich/frequent sampling and a sparse sampling population
pharmacokinetic component in the remaining patients. A second
nested study will compare the effects of ivermectin when
assessed by membrane feeding versus direct skin feeding in all
patients who give additional consent for direct skin feeding.
Primary Objective
The primary objective of the study is to determine the safety,
tolerability, and efficacy of ivermectin doses of 0, 300 and 600
mcg/kg/day for 3 days, when provided with a standard 3-day
course of the antimalarial DP, on mosquito survival.
Secondary Objectives
The secondary objectives of the study are (1) to determine the
effect of different doses of ivermectin on oocyst development;
(2) to determine the pharmacokinetic profile of the different
ivermectin regimens; (3) to determine if ivermectin interacts
with the pharmacokinetics of piperaquine; (4) to determine
whether the addition of ivermectin to DP affects the clinical and
parasitological response to DP treatment; (5) to determine the
role of genetic variants of CYP3A4 activity in metabolizing
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ivermectin; and (6) to determine the effect of direct feeding
versus membrane feeding on mosquito survival.
Design Considerations
Rationale for Ivermectin Doses of 300 and 600
mcg/kg/day
The goal was to design and evaluate a high-dose ivermectin
regimen that could be given daily as adjunct therapy to a 3-day
ACT regimen and that builds on the existing safety data
available from previous studies. The highest dose of ivermectin
used in studies for onchocerciasis is 800 mcg/kg given as a
single dose (ie, about 48 mg in an adult male weighing 60 kg).
The pharmacokinetic profile of this 800 mcg/kg dose was used
to design a 3-day regimen that would achieve a similar
maximum drug concentration (Cmax) after the third dose. Since
the highest dose of ivermectin used in humans that was tested
and found to be well tolerated and safe is 2000 mcg/kg given
as a single dose, this provides a large margin of safety allowing
for inter-individual variation of pharmacokinetics. The middle
group was chosen at 50% of the highest dose to allow for a dose
response in terms of tolerance and efficacy.
Using existing literature data [24,35] we developed a
pharmacokinetic model for ivermectin in humans. Using the
parameter estimates from the model, Monte Carlo simulations
were performed for 1000 theoretical participants assuming a
30% variability in parameter estimates (CL/F 11.8 L/h, Vc/F
195.0 L, Q 18.9 L/h, Vp 882 L, and Ka 0.24/h). The simulations
showed that the Cmax associated with a single dose of 800
mcg/kg was estimated at 108 ng/ml and the 95% percentile as
164 ng/ml (Figure 1). A regimen of 600 mcg/kg/day for 3 days
would give a similar Cmax (111 ng/mL) and corresponding
95% percentile (161 ng/mL) as the single dose 800 mcg/kg
regimen (Figure 2 and Table 2). A regimen of 300 mcg/kg/day
for 3 days would give approximately half those values. The
3-day regimens were predicted to increase the time that
ivermectin concentrations remain above the lethal concentration
50% (LC50) of 16 ng/ml [12] from 46 hours with the 800
mcg/kg single dose to 86 and 162 hours, respectively, with the
300 and 600 mcg/kg/day regimens. The 16 ng/mL threshold
was chosen as this was the median of 3 LC50 concentrations
reported previously [12,14,15]. The simulated data were in
excellent agreement with actual data observed in a dose-finding
study by Guzzo et al 2002 [24], which indicated proportional
pharmacokinetics at doses ranging from 30 to 120 mg, thus
giving confidence in the parameters used in the simulations.
Table 2. Summary of simulated maximum drug concentration and time above lethal concentration 50%.
Days above LC50b (median 5th-95th percentiles)Cmaxa (median 5th-95th percentiles)Ivermectin dosing regimen
1.9 (1.0-5.7)108.1 (75.3-164.4)800 mcg/kg single dose
6.8 (3.8-13.4)111.0 (83.2-161.2)600 mcg/kg/day for 3 days
3.6 (2.8-7.5)55.4 (41.6-80.6)300 mcg/kg/day for 3 days
aCmax: maximum drug concentration (ng/mL).
bLC50: lethal concentration 50% (16ng/mL).
Figure 1. Simulated plasma concentrations of ivermectin 800 mcg/kg single dose. Monte Carlo simulation of 1000 theoretical subjects of ivermectin
concentration with 800 mcg/kg single dose (median: solid line, 5th and 95th percentiles: dashed lines). Cmax is 108.1 ng/mL (CI 75.3-164.4). Time
above LC50 (16 ng/mL; dotted line) is 1.9 days (CI 1.0-5.7).
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Figure 2. Simulated plasma concentrations of ivermectin 600 mcg/kg/day 3-day regimen and 800 mcg/kg/day single dose. Monte Carlo simulation of
1000 theoretical subjects of ivermectin concentrations following 600 mcg/kg/day for 3 days (median: solid line, 5th and 95th percentiles: grey lines),
achieving similar Cmax concentrations compared to 800 mcg/kg single dose (median: dash curve, 95th percentile of Cmax: dashed horizontal line).
The median time above LC50 (16 ng/mL; dotted horizontal line) increases from 1.9 days with 800 mcg/kg single dose to 6.8 days with 600 mcg/kg/day
for 3 days.
Parallel Versus Dose-Escalation Design
The proposed study uses a standard parallel design, comparing
the 2 intervention arms with the placebo arm. This parallel
design, instead of a dose-escalation design (when the lower dose
group would be studied first prior to enrolling patients in the
higher dose group), was considered appropriate because the
Cmax levels and the 95th percentile concentrations in the
proposed highest dose group of 600 mcg/kg/day will be
equivalent to the Cmax found with single dose 800 mcg/kg,
which has been administered to at least 402 patients before as
treatment for onchocerciasis or as part of regulatory studies (see
Table 1). Furthermore, with 30% variation assumed, the Cmax
is estimated to remain well below the Cmax value obtained with
2000 mcg/kg, the highest dose tested and which was
well-tolerated in a dose escalation study.
Why Patients with Malaria?
The study will enroll patients with symptomatic uncomplicated
malaria, instead of asymptomatic patients with malaria parasites
(carriers) or malaria negative individuals who are the
predominant target population in MDA campaigns. However,
it is unlikely that the mosquitocidal effect of ivermectin will
differ much amongst these groups. Preference is given to
symptomatic patients based on the rationale that this study is
labor intensive, requiring very frequent patient follow-up and
blood sampling, and thus requires a major commitment from
study participants. Symptomatic patients, aside from similarly
requiring antimalarial treatment, are more likely to favor hospital
admission and frequent outpatient visits than asymptomatic
patients or other volunteers. The frequent follow-up is
potentially also more beneficial to the patients with symptomatic
malaria than asymptomatic patients.
Justification for Host Genetic Studies
The cytochrome P450s (CYPs) are the major enzymes involved
in drug metabolism. To be able to interpret variations in the
pharmacokinetic drug profiles of piperaquine and ivermectin,
and any drug interactions, we need to determine the genotypes
of the genes encoding CYP enzymes (see above).
Direct Skin Feeding Versus Membrane Feeding
The primary endpoint is based on membrane feeding of
mosquitoes using blood obtained by venepuncture from patients
recently treated with ivermectin. However, a nested sub-study,
in all those that give additional consent, will compare mosquito
mortality rates between clusters fed using standard membrane
feeding versus clusters fed directly (by allowing them to feed
on the arm of the study participant). Ivermectin feeding studies
with direct feeding on humans [13], and cattle [36], have shown
a longer mosquitocidal effect (greater than 2 weeks) in
comparison with studies using membrane feeding (less than 7
days) [14].
We hypothesize that direct feeding could result in higher
mosquito mortality due to potential differences between venous
blood (used in membrane feeding) and blood in subdermal
venuoles and arterioles (the main source of blood for mosquitoes
during direct skin feeding) due to drug accumulation in
subcutaneous fat, dermal, and facial tissue (2- to 3-fold higher
concentrations than in venous blood [37]), or increased exposure
of the mosquito to ivermectin through other means like
perspiration.
There have been no studies conducted directly comparing direct
feeding versus membrane feeding on mosquito mortality
following ivermectin administration. However, previous studies
looking at infectivity (ie, the ability of the vector to develop
oocysts and sporozoites after ingesting gametocytes) showed
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significant differences in terms of infectivity in favor of direct
feeding (odds ratio 2.39) [38]. Although the mechanisms
involved in infectivity studies may differ from studies addressing
the killing effect of ivermectin, this recent infectivity study [38]
indicates the importance of addressing the potential that the
feeding method to expose mosquitoes to ivermectin may be an
important effect modifier and that studies using membrane
feeding may potentially underestimate the true effect of
ivermectin.
Membrane feeding will be used as the primary outcome because
direct skin feeding is labor intensive, may be unpleasant to the
study participants, and result in higher refusal rates.
Study Setting
The study will be conducted in the Jaramogi Oginga Odinga
Teaching and Referral Hospital (JOOTRH) in Kisumu, western
Kenya, a major tertiary care hospital. Almost 25,000 outpatients
are treated for clinical malaria at JOOTRH annually, of which
one-third are laboratory-confirmed. Approximately 20% of
these patients are 18 to 50 years old. Malaria positive individuals
will also be pre-screened at 5 nearby health facilities; those that
pass pre-screening and give consent will be brought to JOOTRH
for screening and all further study procedures.
Eligibility Criteria
Inclusion and exclusion criteria for the study are shown in
Textbox 1.
Textbox 1. Eligibility Criteria
Inclusion Criteria:
• Symptomatic, uncomplicated P. falciparum infection
• Positive malaria microscopy or malaria rapid diagnostic test (RDT, pLDH)
• Age 18 to 50 years
• Provide written informed consent
• Agree to be able to travel to clinic on days 1, 2, 7, 10, 14, 21, and 28
Exclusion Criteria:
• Signs or symptoms of severe malaria
• Unable to provide written informed consent
• Women who are pregnant or breast feeding
• Hypersensitivity to ivermectin or DP
• Rate corrected QT interval (QTc) of greater than 460 ms on electrocardiogram (ECG)
• Body mass index (BMI) below 16 or above 32 kg/m2
• Hemoglobin (Hb) concentration below 9 g/dL
• Taken ivermectin in the last month
• Taken DP in the last 12 weeks
• Loa loa as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia,
Gabon, Nigeria and Sudan
• History and/or symptoms indicating chronic illness
• Current use of tuberculosis or anti-retroviral medication
• Previously enrolled in the same study
Trial Medications and Interventions
Participants will be randomized to one of the following 3 arms:
(1) the “0 mcg/kg” (placebo) arm consisting of DP plus
ivermectin-placebo 600 mcg/kg/day for 3 days, (2) the “300
mcg/kg” arm consisting of DP plus ivermectin 300 mcg/kg/day
and ivermectin-placebo 300 mcg/kg/day for 3 days, or (3) the
“600 mcg/kg” arm consisting of DP plus ivermectin 600
mcg/kg/day for 3 days. Patients will receive their weight-based
doses of DP and ivermectin/placebo. Each dose will be given
as directly observed therapy by study staff, after which
participants will be monitored for 30 minutes for any vomiting
and adverse reactions. If vomiting occurs within 30 minutes,
then the participant will be withdrawn from the study, DP will
be re-administered, and no further ivermectin will be given.
Dihydroartemisinin-Piperaquine
DP was selected as the drug of choice as it is the most likely
candidate to be used in future MDA campaigns because of the
longer prophylactic effect against malaria (4 to 6 weeks)
compared with 2 to 3 weeks with artemether-lumefantrine (AL).
Each participant will receive a weight-based dose of DP 320/40
mg (Eurartesim, Sigma Tau, Italy) as per the product insert (36
to 75 kg: 3 tablets, greater than 75 kg: 4 tablets) once a day for
3 days.
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Ivermectin and Placebo
Ivermectin and/or placebo 6 mg tablets (Iver P, Laboratorio
Elea, Argentina) will be administered per bodyweight. The 600
mcg/kg/day arm will receive only ivermectin tablets, the 300
mcg/kg/day arm will receive half the number of ivermectin
tablets and an equal number of placebo tablets, and the 0
mcg/kg/day arm will receive only placebo tablets. All
participants will receive the same total number of tablets once
a day for 3 days based on their bodyweight (45 to 55 kg: 5
tablets, 55 to 65 kg: 6 tablets, 65 to 75 kg: 7 tablets, 75 to 85
kg: 8 tablets, 85 to 95 kg: 9 tablets, 95 to 105 kg: 10 tablets).
Endpoints and Outcome Measures
Primary Efficacy Outcome
The primary efficacy outcome is mosquito survival at 14 days
after feeding on blood taken from study participants who started
the 3-day ivermectin and DP regimen 7 days earlier (Multimedia
Appendix 1).
Secondary Outcomes
Secondary outcomes include (1) mosquito survival at each day,
up to day 21 or 28, after each feeding experiments performed
at 0, 2 days plus 4h, 7, 10, 14, 21, and 28 days after start of
treatment; (2) occurrence of oocysts from day 10 onwards after
each feeding as determined by polymerase chain reaction (PCR);
(3) malaria clinical and parasitological treatment response by
day 28; and (4) plasma concentration profiles of piperaquine
and ivermectin as described by standard pharmacokinetic
metrics, for example area under the curve measurements from
time zero to infinity (AUC0-∞), time zero to the time of the last
measurable concentration (AUC0-tlast), Cmax, and plasma
half-life, time to maximum plasma concentration, etc
(Multimedia Appendix 1).
Tolerability and Safety Endpoints
Tolerability and safety endpoints are shown in Textbox 2.
Textbox 2. Tolerability and safety endpoints.
Tolerability
• Any adverse events assessed in general toxicity questionnaires asked at each study visit
Safety
• Primary
Mydriasis quantitated by pupillometry [24]
• Secondary
• Central nervous system (CNS) effects
• General toxicity
• Serious adverse events
• Hemoglobin concentrations
• QTc interval (see below “Electrocardiogram Monitoring”)
Participants’ Timeline
Overview Study Phases
The study plan and schedule of assessment is provided in
Multimedia Appendix 1. The participant’s timeline will consist
of a pre-screening visit (visit 1), consent, screening, and
enrolment visit (visit 2), 2 subsequent treatment visits (3 and
4) on days 1 and 2, and 6 follow-up visits for assessment of
efficacy parameters (visits 5 to 10). For those enrolled in the
pharmacokinetic study additional visits for drug level sample
are required as outlined in Multimedia Appendix 2.
Visits 1 and 2: Pre-Screening, Consent, Screening and
Enrolment
Patients presenting to the outpatient departments of the study
clinics will be pre-screened to determine if they meet readily
apparent study eligibility criteria including (1) age 18 to 50
years; (2) uncomplicated malaria; (3) in Kisumu next 4 weeks;
(4) hemoglobin (Hb) less than or equal to 9g/dL (if already
performed); (5) not pregnant or breast feeding; (6) no known
chronic illness; and (7) not previously enrolled in IVERMAL.
Patients passing pre-screening will be approached to obtain
consent. For those consenting, study-specific screening
procedures will take place, including demographics, full history,
past medication use, travel history (Loa endemic countries),
physical examination, electrocardiogram (ECG), pupillometry,
and laboratory tests (to confirm malaria, Hb, and pregnancy).
Those fulfilling all enrolment inclusion criteria and not meeting
any exclusion criteria will be enrolled into the study,
randomized, and treated with the appropriate tablets according
to study arm (Textbox 1). Estimated duration is 1.5 to 2.0 hours.
Visits 3 and 4: Treatment Visits
Participants will return to the outpatient clinic on day 1 and 2
for the 2nd and 3rd dose of study drugs. In exceptional cases a
participant will be permitted to take the study medication at
home or the participant will be visited at home by study staff
to administer the medication. A follow-up ECG will be taken
just prior to and 4 to 6 hours after the last dose of DP plus
ivermectin on day 2.
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Visits 5 to 10: Scheduled Follow-Up Visits
Participants will return to the outpatient clinic for follow-up as
specified (see Multimedia Appendix 1). A questionnaire will
assess the presence of signs and symptoms, including any
adverse effects. A brief clinical examination will be performed
and a venous blood sample will be taken for malaria diagnosis,
Hb, and drug levels. On visits 5 (day 2 plus 4h) and 6 (day 7),
drug levels will also be determined in a finger prick sample. A
final follow-up ECG will be taken on the day 28 visit.
Participants will be asked to provide telephone numbers so that
study staff may make every effort to follow-up participants who
have missed scheduled visits (Multimedia Appendix 2, section
8.5.5, page 31).
Unscheduled Visits
At any time, participants displaying signs or symptoms of severe
malaria will be admitted to the inpatient ward for further
evaluation and treatment free of charge. Blood samples for
malaria smears, parasite genetics (filter paper dried blood spots)
and Hb will be taken if clinically indicated (e.g. documented
fever greater than or equal to 37.5°C axillary, or a history of
fever in the last 24 hours).
Sample Size
The study requires a total of 141 participants (47 participants
in the 0, 300, and 600 mcg/kg/day groups each). This is powered
at 80% to detect a relative increase of 30% (RR 1.300) in the
14-day post-feeding mortality rate (primary outcome) from 24%
in the control group (0 mcg/kg ivermectin) to 31.2% in the 300
mcg/kg/day group, and a 25% (RR 1.246) increase from 31.2%
with 300 mcg/kg/day to 38.9% in 600 mcg/kg/day recipients,
measured from blood taken 7 days after the start of intake of
ivermectin and using clusters of 100 anopheline mosquitoes
allowing for 10% non-feeders (alpha=.05). The same sample
size would give 90% power to detect a 35% (RR 1.348) increase
from 24% (0 mcg/kg/day) to 32.4% (300 mcg/kg/day), and
27.7% increase (RR 1.285) from 32.4% (300 mcg/kg/day) to
41.3% (600 mcg/kg/day). The calculations assume an
intracluster correlation coefficient (ICC) of .0622 and allow for
6.5% loss-to follow-up of participants by day 7 (ie, 44 of the
47 patients per arm contribute to the primary analysis) [14]. The
10% non-feeding rate is based on current data from the same
laboratories at Kenya Medical Research Institute (KEMRI),
Kisian, Kenya. The 24% mortality rate estimate by day 14
post-feeding in the control arm is average of observation at
KEMRI (18.3%) and in a recent study in Burkina Faso, which
showed a 21.2% mortality by day 10 [14], which when
extrapolated with 4 additional days predicted a mortality of
29.7% by day 14. The ICC value of .0622 was calculated using
data from the recent study in Burkina Faso (Bousema, personal
communications) [14].
Assignment of Interventions
Allocation
The study will use stratified randomization (4 strata) by body
mass index (BMI: high/low) and sex (male/female) as these are
important determinants of the pharmacokinetics of ivermectin
[14]. The high/low BMI thresholds are 23 kg/m2 and 21 kg/m2,
for females and males respectively. Participants will be
randomly assigned to 1 of the 3 study arms. The study
statistician will computer-generate a randomization sequence
using permuted block randomization with fixed block sizes.
Blinding
The study will be double-blinded to participants and study staff.
Allocation concealment will be achieved by use of sealed opaque
envelopes. All study participants in all 3 arms will receive
standard dose DP, and also active (600 mcg/kg/day arm),
placebo (0 mcg/kg/day arm), or a combination of active and
placebo ivermectin tablets (300 mcg/kg/day arm), such that each
arm receives the same number of tablets in each weight strata.
Pharmacokinetic Studies
Overview
The first 36 patients to give additional consent for rich
pharmacokinetics (approximately 12 per arm), will be enrolled
in a rich pharmacokinetic study using frequent sampling per
individual (26 samples per patient, see Multimedia Appendix
2 [Table 2, page 15]) to determine the detailed pharmacokinetic
profile of the 2 regimens and assess whether any drug interaction
occurs with piperaquine that is of clinical relevance. The
remaining patients (approximately 35 per arm) will contribute
to a population pharmacokinetic study consisting of sparse
pharmacokinetic sampling with a maximum of 13 samples per
patient including baseline (1 venous sample), 6 scheduled visits
as part of the main trial (6 venous and 2 finger prick samples),
and 2 extra visits for population pharmacokinetic sampling (2
venous and 2 finger prick samples).
The rich and population pharmacokinetic studies combined will
allow us to determine the main sources and correlates of
variability in drug concentrations (for both ivermectin and
piperaquine), including demographic, pathophysiological, such
as BMI and gender, and other factors that might alter
dose-concentration relationships. As this is a placebo controlled
trial, the sampling methodology for the 47 patients in the
ivermectin-placebo arm will be identical to that used for the
300 and 600 mcg/kg arms. The patients in the
placebo-ivermectin arm will allow us to determine the
piperaquine kinetic profile in the absence of ivermectin.
Finger prick blood draws will be performed at a maximum of
4 time points in addition to the venous blood draws. The aim is
to compare the capillary and venous drug concentration levels
as it has been hypothesized that these might differ for
ivermectin, similar to other drugs including piperaquine. A
difference between capillary and venous drug concentrations
could help further explain any observed difference in mosquito
mortality between membrane and direct skin feeding (see also
above “Direct Skin Feeding versus Membrane Feeding”).
Standard Pharmacokinetic Study (Rich Sampling)
All of the rich pharmacokinetic participants (approximately 12
per arm) will have venous blood sampled (4 ml whole blood to
obtain 2 ml plasma, or 5.2 mL of whole blood if coinciding with
a scheduled follow-up visit for the main trial) at baseline and
each of 21 follow-up time points listed in Multimedia Appendix
2 (Table 2, page 15). In addition, 4 finger pricks (0.5 mL whole
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blood) will be taken at days 2 plus 4 h, 3, 4 and 7. The total
blood volume to be drawn from these patients is 98.4 mL whole
blood over 28 days, 82.8 mL of which is taken during the first
10 days. If more than 2 patients withdraw from the study without
giving more than 12 samples, the withdrawing patients will be
replaced. Outpatients who consent to the standard
pharmacokinetic study will be admitted in the hospital for the
first 3 days.
Population Pharmacokinetics (Sparse Sampling)
Each of remaining patients (approximately 35 per arm), not
enrolled in the rich pharmacokinetic sub-study, contribute to
the population pharmacokinetic study, which consists of 13
sampling points (see Multimedia Appendix 2, page 15). Seven
of the 13 time points coincide with the timing of the sample for
membrane feeding (including the baseline sample), and thus do
not require an extra venepuncture (ie, days 0, 2 [52 hrs; 4 hrs
after last dose of ivermectin], days 7, 10, 14, 21 and 28). Six of
the 13 time points are specific for the population
pharmacokinetic study and will require an extra venepuncture
(50, 54, 60, 72, 96 and 120 hours, ie, 2, 6, 12, 24, 48, and 120
hrs after the third and last dose of ivermectin). To ensure an
equal distribution of samples across the different sampling time
points for the extra 2 visits, participants will be divided into 4
extra sampling groups; each of which will contribute 2 extra
time points, with the exception of group B which will contribute
1 extra time point (Table 3). In addition, a maximum of 4 finger
pricks (0.5 mL whole blood) will be taken at days 2 plus 4 h,
7, and at each of the 2 population pharmacokinetic visits. Thus
the total number of samples per participant will be 13 and
involve a total of 46.4 mL of whole blood (including the 7
samples for the main trial). The sampling times will be noted
in the case record form (CRF), and the patient given a reminder
card to return to clinic at their allocated time.
Table 3. Schedule of extra sampling points for population pharmacokinetic study by 4 sampling groups.
Number per sampling strataSample absolute timea, hoursSample daya (plus hours after 3rd ivermectin dose)Subject Group
9502.08 (+2 hours)A
542.25 (+6 hours)
8542.25 (+6 hours)B
9602.50 (+12 hours)C
723 (+24 hours)
9964 (+48 hours)D
1205 (+72 hours)
35Total
aExtra visits that need to be made specifically for the population pharmacokinetic samples. The other 7 visits contributing to the population pharmacokinetic
analysis (days 0, 2, 7, 10, 14, 21, 28) coincide with the scheduled visits in the main trial. The first day is day=0; day 1 starts 24 hours after the first dose.
The allocation to the sampling strata will be at random. However, if a participant indicates he/she is not able to attend a certain follow-up day, the strata
can be replaced by another sampling schedule (within the same allocation strata, eg, for BMI, gender, etc) until all 15 or 16 allocations per sampling
group have been used.
In anticipation of a 40% refusal rate or loss to follow-up, we
estimate that the combined rich and population pharmacokinetic
sub-studies will contribute 361 samples including 47 baseline
samples (100%) and 314 (60%) follow-up samples out of a
potential 524 follow-up samples across 22 sampling time points
after baseline, 20 of which overlap, with a total of 12 to 47
observations per time point (see Multimedia Appendix 2,Table
2, page 15).
Laboratory Procedure
Mosquito Colonies
See the “Procedures for Assessing Efficacy and Safety
Parameters” section above for use of mosquito colonies and
procedures to assess the primary (mosquito survival) and
secondary entomological endpoints (sporogony). The section
below describes the maintenance of the mosquito colonies.
The mosquito colony used in this study will be An. gambiae s.s.
Kisumu strain, originally from Kisumu, Kenya. The strain is
maintained at the KEMRI/Centre for Global Health Research
(CGHR) insectaries and is susceptible to all insecticides
approved by the World Health Organization (WHO). When
performing membrane feeds on infected human blood,
mosquitoes will be kept and fed in cages or paper cups. The
cages or paper cups will be kept in a temperature- and humidity-
controlled insectary. The feeding and the storage of live infected
mosquitoes will occur in sealed rooms with at least 2 doors
and/or barriers separating the inner rooms from the outside.
Mosquitoes will not be removed from their enclosures, with
exception of the cage for oocyst determination. During
transportation, live infected mosquitoes will be transported
within paper cups that are covered with a moist towel and
enclosed within locked cool-boxes to remove any chances of
escape. The cool-boxes will only be opened within the confines
of a double door insectary.
Ivermectin Plasma Concentration
The LC50 has been previously estimated using spiked blood
(blood to which known concentrations of ivermectin are added)
in membrane feeding assays [12,15]. We will test the
concentration of ivermectin in human plasma in order to provide
data for a pharmacokinetic/dynamic analysis to obtain estimates
of the 10-day LC50 and time post-treatment that the transmission
blocking effects (on mosquito survival and oocyst rates) lasts.
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Hemoglobin Testing
Hb will be tested using HemoCue (Angelholm, Sweden)
photometers.
Thick and Thin Blood Smears for Malaria
Thick and thin blood films for parasite counts will be obtained
and examined. Malaria parasites will be counted against 200
high power fields before a slide is declared negative [39].
Processing of Pharmacokinetic Samples
Plasma will be stored locally on site at -20°C or in liquid
nitrogen and shipped to a central laboratory for storage at -70°C
prior to batch analysis at the Liverpool School of Tropical
Medicine. Samples will be shipped in dry ice to the laboratories
in Liverpool, United Kingdom where the plasma concentrations
of ivermectin and piperaquine will be determined using assays
validated to international Food and Drug Administration (FDA)
standards. Plasma concentration-time data will be used to
evaluate pharmacokinetic parameters including CL/F (oral
clearance), V/F (oral volume of distribution), and Ka (absorption
rate constant) using population pharmacokinetic methods. Area
under the curve (AUC) and half-life will also be calculated.
Statistical Methods
A study statistical analytical plan for the final analysis, that
supersedes the study protocol, has been drawn up during the
course of the study before the unblinding of data at database
lock (see Multimedia Appendix 3).
Procedures for Assessing Efficacy and Safety
Parameters
Membrane Feeding Procedure
The following procedures will be conducted in accordance with
a standard membrane feeding protocol [40]. A 1 mL sample of
the participant’s blood will be drawn into a sodium heparin
(coated) tube pre-heated to 37.5°C. Within 2 minutes the blood
will be placed in a glass bell membrane feeding system and
cups of mosquitoes will commence feeding. For each feeding
3 new cups (2 cups for mosquito survival, and 1 cup for oocysts)
of 50, 3 to 5 day old female, insectary-reared An. gambiae s.s.
mosquitoes will be presented to the membrane feeder for 20
minutes. The number of mosquitoes with an engorged abdomen
will be counted and those with lean abdomens discarded. Each
day up to day 28 (mosquito survival cups) or day 10 (oocyst
cup), the number of dead mosquitoes will be counted and
removed. After the initial feeding on human blood, the
mosquitoes will be kept in an incubator and maintained on sugar
feeds. Insectary staff assessing mosquito survival and oocyst
development will be blinded to all characteristics of the cups
(ie, participant identification, study arm, duration between
treatment and feeding, and feeding method).
Primary Efficacy Outcome
The primary outcome will be the survival of mosquitoes (from
the 2 mosquito survival cups) at 14 days after feeding on blood
taken from study participants who started the 3-day ivermectin
and DP regimen 7 days earlier.
Secondary Efficacy Outcomes
Although the primary endpoint is assessed at day 14, the study
will collect survival data of mosquitoes at each day up to day
21 or 28 for the mosquito survival cups and day 10 in the case
of oocyst cups, after each feeding experiments performed at 0,
2 days plus 4h, 7, 10, 14, 21, 28 days after start of treatment.
The methods will be identical to that described for the primary
outcome where each day beyond day 14 the number of dead
mosquitoes will be counted and removed until day 28 inclusive.
The exact number of follow-up days (21 or 28 days) will be
subject to logistical constraints of the laboratory, and mortality
rates in the mosquito populations which will be further
determined prior to the start of the study. The aim is to determine
the median time to mortality, which requires that at least half
of the mosquito population has died in each arm. It is anticipated
that 21 days will be sufficient.
Direct Skin Feeding and Mosquito Survival
A sub-study will determine the effect of direct feeding versus
membrane feeding on mosquito survival, after feeding
experiments performed at 7 days after the start of treatment. In
direct skin feeding assays, 1 cup of 50 mosquitoes is placed
directly on the skin of the human host and allowed to feed for
15 minutes (Figure 3). Further procedures after direct feeding
are identical to those after membrane feeding.
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Figure 3. Difference between membrane feeding and direct feeding (adapted from Bousema et al 2012 [38]).
Infectivity to Mosquitoes (Oocyst Polymerase Chain
Reaction)
On day 10 post membrane feeding, when residual DNA from
the blood meal is highly unlikely [14,41,42], all surviving
mosquitoes in the oocyst cup will be preserved to determine
oocyst prevalence by PCR. Mosquitoes will be homogenized
and processed, in 2 pooled batches per cup.
Asexual Treatment Response and Parasite Clearance
Standard methods will be used to assess the in vivo treatment
response to DP using the microscopy and rapid diagnostic test
(RDT) data collected at each scheduled follow-up visit and
criteria described by World Wide Antimalarial Resistance
Network (WWARN) [43].
Pupillometry
In animal studies, mydriasis has been shown to be a first sign
of ivermectin toxicity. To monitor for possible toxicity, pupil
diameter size will be measured at baseline and each scheduled
visit using a portable, single-button activation, battery operated
hand-held pupillometry device that very accurately measures
pupil size requiring no calibration (NeurOptics VIP-200 Variable
Pupillometer). This device measures the pupil 30 times per
second over a 5-second period and provides the average pupil
diameter and standard deviation (+/- 0.1 mm). The
measurements will be taken in a dark room with standardized
lighting conditions.
Electrocardiogram Monitoring
Piperaquine can potentially lead to prolongation of the rate
corrected QT interval (QTc) on an electrocardiogram (ECG).
To exclude a possible interaction between ivermectin and
piperaquine leading to an increased QTc interval, 12-lead ECGs
will be performed to measure the QTc interval at baseline, day
2 pre last dose, day 2 at 4 to 6h post last dose and again at day
28. The day 28 sample is included as it can be difficult to assess
a true baseline in patients with acute malaria, as malaria and
fever are known to increase the heart rate and decrease the QTc
interval. On day 28 most, if not all, patients will be malaria free
and residual piperaquine levels low enough not to affect QTc
intervals. A portable ECG machine (MAC 600, General Electric,
US) will be used with automated ECG interpretation. Patients
with a QTc value of 480 ms or greater prior to the last dose of
DP will not receive the last dose of DP, but receive a full course
of artemether lumefantrine instead. Fridericia’s correction will
be used to calculate the QTc values for final data analysis using
the following equation: QTc = QT/RR0.33.
Adverse Events
Adverse events and serious adverse events will be monitored,
managed, and recorded during the course of the study. They
will be recorded and tabulated for each treatment arm, overall,
and per body system (see Multimedia Appendix 2, Section 9.6,
Safety Monitoring and Reporting).
Ethics Approval and Consent to Participate
This protocol, the informed consent documents, and patient
information sheets have been reviewed and approved by the
Research Ethics Committees at KEMRI (protocol #2775), LSTM
(protocol #14.002), and JOOTRH. The Centers for Disease
Control and Prevention (CDC, protocol #6720) gave approval
for reliance on the KEMRI institutional review board (see
Multimedia Appendix 4 Ethics Approvals KEMRI, CDC,
LSTM, and JOOTRH).
Results
Recruitment started July 20, 2015. Enrolment was completed
May 2016, and clinical follow-up was completed 4 weeks later
in June 2016. Mosquito follow-up was completed in July 2016,
4 weeks after completion of the clinical follow-up. Unblinding
and analysis will commence once the database has been
completed, cleaned, and locked.
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Discussion
Principal Findings
New strategies for malaria control, and eventually for
elimination are critically needed. This study will seek to answer
the question as to whether higher doses of ivermectin (300 and
600 mcg/kg/day for 3 days) are well tolerated, safe, and result
in longer durations of mosquitocidal effects than standard 150
to 200 mcg/kg single dose treatments. This study requires major
infrastructure and collaboration, as it brings together the
disciplines of clinical medicine, entomology, parasitology,
pharmacokinetics, and pharmacogenetics in a clinical trial. For
this study, 141 patients and 150,000 mosquitoes will each be
followed for 28 days. For this reason, this trial has been placed
at the KEMRI, CDC, and LSTM collaboration in western Kenya,
a research site, which in collaboration with its partners, has been
conducting research for over 35 years and has the capacity to
undertake such a trial. An important possible limitation of this
study is that it will enroll participants with symptomatic malaria,
whereas possible future applications of high-dose ivermectin
may involve MDA with ACT’s targeting asymptomatic carriers
and uninfected individuals in addition to symptomatic patients.
Should this study show promising results, then the next step
will be to evaluate safety, tolerability, and efficacy in younger
age groups with the ultimate goal of testing its effect on malaria
transmission when applied at the population level through MDA.
Conclusion
High-dose ivermectin, if found to be safe and well tolerated,
could potentially complement existing tools for malaria
elimination.
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Abbreviations
ACT: artemisinin-based combination therapy
AUC: area under the curve
CDC: Centers for Disease Control and Prevention
Cmax: maximum drug concentration
CYP: cytochrome P450
CYP3A4: cytochrome-P450 3A4
DHA: dihydroartemisinin
DP: dihydroartemisinin-piperaquine
ECG: electrocardiogram
Hb: hemoglobin
ICC: intracluster correlation coefficient
JOOTRH: Jaramogi Oginga Odinga Teaching and Referral Hospital
KEMRI: Kenya Medical Research Institute
LC50: lethal concentration 50%
LLINS: long-lasting insecticide treated nets
LSTM: Liverpool School of Tropical Medicine
MDA: mass drug administration
PCR: polymerase chain reaction
RDT: rapid diagnostic test
QTc: rate corrected QT interval on an electrocardiogram
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